June 7th 2025
A new report suggests a noninvasive means to evaluate portal hypertension in patients with BCR::ABL1-negative myeloproliferative neoplasms.
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
Lingering Unknowns Amid Lung Cancer Breakthroughs: Martin Edelman, MD
April 22nd 2025Although immunotherapies and biomarker-driven interventions have transformed lung cancer outcomes, Martin Edelman, MD, Fox Chase Cancer Center, highlighted the present challenge hindering clinicians' abilities to anticipate patients' treatment responses.
Watch
New Hope and Persistent Challenges for MASH Treatment: Naim Alkhouri, MD
April 17th 2025Recent advances have marked a turning point for the treatment noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), with more therapies on the horizon to hopefully better address patients' cirrhosis, explained Naim Alkhouri, MD.
Watch
Physician-Led Tech Firms Use AI to Counter Drug Denials and Augment Appeals
April 16th 2025As drug denials increase, experts discuss the importance of optimizing data to keep up with these changes and implementing artificial intelligence (AI) to reduce the burden on providers and ensure patient access to care and treatment.
Watch
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Lifestyle Interventions, Statins, Among Keys to Mitigating CVD Risk in MASLD/MASH
April 15th 2025A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like peptide 1 (GLP-1) receptor agonists for liver conditions.
Read More